Rucaparib Maintenance Yields PFS Benefit Across HRD-Negative Subgroups of High-Grade Ovarian Cancer
OncLive,
Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade…
Vanda Salutari, MD, discusses the efficacy of first-line rucaparib maintenance therapy in patients with HRD-negative high-grade…
Rucaparib maintenance therapy provided consistent benefits across all subgroups of patients grouped by prognostic factors of…
Rucaparib improved PFS in HRD-negative ovarian cancer patients, with a median PFS of 12.1 months versus 9.1 months for placebo.
Ovarian cancer remains one of the most challenging malignancies to manage, with high morbidity and mortality rates due to the…